Showing results (2491-2500 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|September 7, 2026
Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology AppraisalsSaul Stevens, Maxwell S Barnish, Alan Lovell, et al.
Pharmacoeconomics|September 10, 2026
Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling ApproachNiels Lund, Christopher Lübker, Andreas Rasche, et al.
Pharmacoeconomics|September 16, 2026
A Systematic Review of Reporting of Validation Efforts for Cancer Health Economic Decision ModelsPingping Li, Min Zhao, Yihe Tian, et al.
Pharmacoeconomics|September 7, 2026
Value of Knowing the Risk of Developing a Neurodegenerative Disease: A Discrete Choice ExperimentPatricia G Synnott, Daniel A Ollendorf, Steven M Kymes, et al.
Pharmacoeconomics|September 30, 2026
Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson's Disease: Evidence Review and Expert OpinionAnshul Shah, Richard Dodel, Saifuddin Kharawala, et al.
Pharmacoeconomics|October 23, 2026
Patient-Centered Value Elements in the Economic Evaluation of Chronic Obstructive Pulmonary Disease (COPD): A Targeted Review of Cost-Effectiveness AnalysesNabin Poudel, Leah Lodise, Jiwon Oh, et al.
Pharmacoeconomics|August 12, 2003
Defining monetary values for quality of life improvements: an exploratory studyJean Lachaine, Claudine Laurier, André-Pierre Contandriopoulos
Pharmacoeconomics|August 12, 2003
Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromesGreg L Plosker, Tim Ibbotson
Pharmacoeconomics|May 20, 2003
Labour force participation among individuals with hepatitis C in the USPhilip Jacobs, Ying Chu Ng, Tania Stafinski, et al.
Pharmacoeconomics|May 20, 2003
The cost effectiveness of ACE inhibitors as first-line antihypertensive therapyAlain J Nordmann, Murray Krahn, Alexander G Logan, et al.
Pageof 336